| scholarly article | Q13442814 |
| P50 | author | Des R. Richardson | Q37369291 |
| P2093 | author name string | Zaklina Kovacevic | |
| Rayan S Moussa | |||
| P2860 | cites work | Multiple murine double minute gene 2 (MDM2) proteins are induced by ultraviolet light | Q74602523 |
| The influence of radiation and chemotherapy-related DNA strand breaks on carcinogenesis: an evaluation | Q77882789 | ||
| The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation | Q77974898 | ||
| Crystal and molecular structure of 2-hydroxy-1-naphthaldehyde isonicotinoyl hydrazone (NIH) and its iron(III) complex: an iron chelator with anti-tumour activity | Q78103293 | ||
| Cytoplasmic p21(WAF1/CIP1) expression in human hepatocellular carcinomas | Q80215341 | ||
| p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities | Q22003973 | ||
| New functional activities for the p21 family of CDK inhibitors | Q24313427 | ||
| The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases | Q24319848 | ||
| Exploitation of KESTREL to identify NDRG family members as physiological substrates for SGK1 and GSK3 | Q24528133 | ||
| MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation | Q24537700 | ||
| Cytoplasmic p21WAF1/CIP1 expression is correlated with HER-2/ neu in breast cancer and is an independent predictor of prognosis | Q24802985 | ||
| WAF1, a potential mediator of p53 tumor suppression | Q27861121 | ||
| A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage | Q28138556 | ||
| P21Waf1/Cip1 dysfunction in neuroblastoma: a novel mechanism of attenuating G0-G1 cell cycle arrest | Q28184441 | ||
| Lost in transcription: p21 repression, mechanisms, and consequences | Q28251319 | ||
| p21 is a universal inhibitor of cyclin kinases | Q28257305 | ||
| The p53-mdm-2 autoregulatory feedback loop | Q28609811 | ||
| p53: puzzle and paradigm | Q29618407 | ||
| p21 in cancer: intricate networks and multiple activities | Q30436015 | ||
| A novel function of emodin: enhancement of the nucleotide excision repair of UV- and cisplatin-induced DNA damage in human cells | Q30732406 | ||
| p63 and p73 transcriptionally regulate genes involved in DNA repair | Q33509508 | ||
| The p53 family: same response, different signals? | Q33720564 | ||
| Regulation and function of the p53-related proteins: same family, different rules | Q33885465 | ||
| Mitomycin C inhibits ribosomal RNA: a novel cytotoxic mechanism for bioreductive drugs | Q33911220 | ||
| Stress signals utilize multiple pathways to stabilize p53 | Q33963268 | ||
| Tuning cell cycle regulation with an iron key. | Q34005956 | ||
| p21(WAF1/Cip1): more than a break to the cell cycle? | Q34020123 | ||
| Epstein-Barr virus latent membrane protein-2A-induced DeltaNp63alpha expression is associated with impaired epithelial-cell differentiation | Q34029669 | ||
| Oncogenic functions of tumour suppressor p21(Waf1/Cip1/Sdi1): association with cell senescence and tumour-promoting activities of stromal fibroblasts | Q34552889 | ||
| p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions | Q34727942 | ||
| The Delta Np63 alpha phosphoprotein binds the p21 and 14-3-3 sigma promoters in vivo and has transcriptional repressor activity that is reduced by Hay-Wells syndrome-derived mutations | Q34784078 | ||
| The role of iron in cell cycle progression and the proliferation of neoplastic cells | Q34872120 | ||
| MDM2 promotes invasion and metastasis in invasive ductal breast carcinoma by inducing matrix metalloproteinase-9. | Q35043588 | ||
| A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics | Q35075541 | ||
| Di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes multidrug resistance by a novel mechanism involving the hijacking of lysosomal P-glycoprotein (Pgp). | Q35351758 | ||
| N-myc downstream regulated gene 1 modulates Wnt-β-catenin signalling and pleiotropically suppresses metastasis | Q42578068 | ||
| Loss of nuclear p21(Cip1/WAF1) during neoplastic progression to metastasis in gamma-irradiated p21 hemizygous mice | Q42610205 | ||
| p76(MDM2) inhibits the ability of p90(MDM2) to destabilize p53. | Q42805280 | ||
| The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: The mechanisms involved in inhibiting cell-cycle progression | Q43684729 | ||
| Effects of a single course of deferoxamine in neuroblastoma patients | Q43928023 | ||
| EVI1 targets ΔNp63 and upregulates the cyclin dependent kinase inhibitor p21 independent of p53 to delay cell cycle progression and cell proliferation in colon cancer cells | Q43941306 | ||
| Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. | Q44285265 | ||
| Potent iron chelators increase the mRNA levels of the universal cyclin-dependent kinase inhibitor p21(CIP1/WAF1), but paradoxically inhibit its translation: a potential mechanism of cell cycle dysregulation | Q44478701 | ||
| The effect of potent iron chelators on the regulation of p53: examination of the expression, localization and DNA-binding activity of p53 and the transactivation of WAF1. | Q44517401 | ||
| Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells | Q46165431 | ||
| Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. | Q47586142 | ||
| A novel protein with strong homology to the tumor suppressor p53. | Q48044761 | ||
| The metastasis suppressor, N-myc downstream regulated gene 1 (NDRG1), upregulates p21 via p53-independent mechanisms. | Q53261745 | ||
| p53 and Delta Np63 alpha differentially bind and regulate target genes involved in cell cycle arrest, DNA repair and apoptosis. | Q53561930 | ||
| Characterization of corneal pannus removed from patients with total limbal stem cell deficiency. | Q54704777 | ||
| DNA sequence specificity of mitomycin cross-linking | Q57260357 | ||
| Dipyridyl Thiosemicarbazone Chelators with Potent and Selective Antitumor Activity Form Iron Complexes with Redox Activity | Q61050477 | ||
| In vitro and in vivo effects of deferoxamine in neonatal acute leukemia | Q68813866 | ||
| Antineuroblastoma activity of desferoxamine in human cell lines | Q69745679 | ||
| Deferoxamine: a reversible S-phase inhibitor of human lymphocyte proliferation | Q70372959 | ||
| Normal p53 status and function despite the development of drug resistance in human breast cancer cells | Q70902160 | ||
| Iron deprivation results in an increase in p53 expression | Q70975280 | ||
| Deferoxamine in children with recurrent neuroblastoma | Q72493590 | ||
| Effect of passage number on cellular response to DNA-damaging agents: cell survival and gene expression | Q73145232 | ||
| Differential expression of p16/p21/p27 and cyclin D1/D3, and their relationships to cell proliferation, apoptosis, and tumour progression in invasive ductal carcinoma of the breast | Q73820427 | ||
| An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2 | Q74332873 | ||
| Mdm2: A regulator of cell growth and death | Q35572466 | ||
| p21Waf1/Cip1 as a therapeutic target in breast and other cancers | Q35620816 | ||
| Human MDM2 isoforms translated differentially on constitutive versus p53-regulated transcripts have distinct functions in the p53/MDM2 and TSG101/MDM2 feedback control loops | Q35641639 | ||
| The proto-oncogene c-Src and its downstream signaling pathways are inhibited by the metastasis suppressor, NDRG1. | Q35832242 | ||
| Iron chelators in cancer chemotherapy | Q35972670 | ||
| The evolution of iron chelators for the treatment of iron overload disease and cancer. | Q36355224 | ||
| The intricacies of p21 phosphorylation: protein/protein interactions, subcellular localization and stability | Q36507200 | ||
| Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage | Q36557538 | ||
| WAF1 retards S-phase progression primarily by inhibition of cyclin-dependent kinases | Q36570903 | ||
| Dp44mT targets the AKT, TGF-β and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells. | Q36594041 | ||
| DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways | Q36647845 | ||
| Proteolytic cleavage and truncation of NDRG1 in human prostate cancer cells, but not normal prostate epithelial cells. | Q36921180 | ||
| Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors. | Q37550486 | ||
| Novel chelators for cancer treatment: where are we now? | Q37994291 | ||
| Molecular functions of the iron-regulated metastasis suppressor, NDRG1, and its potential as a molecular target for cancer therapy. | Q38165627 | ||
| NDRG1 as a molecular target to inhibit the epithelial-mesenchymal transition: the case for developing inhibitors of metastasis | Q38243890 | ||
| MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53. | Q38345102 | ||
| Relationship between expression of KAI1 metastasis suppressor gene, mRNA levels and p53 in human bladder and prostate cancer cell lines. | Q38359952 | ||
| The metastasis suppressor NDRG1 modulates the phosphorylation and nuclear translocation of β-catenin through mechanisms involving FRAT1 and PAK4. | Q38994899 | ||
| Targeting the metastasis suppressor, NDRG1, using novel iron chelators: regulation of stress fiber-mediated tumor cell migration via modulation of the ROCK1/pMLC2 signaling pathway | Q39236830 | ||
| The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action | Q39257764 | ||
| The iron-regulated metastasis suppressor NDRG1 targets NEDD4L, PTEN, and SMAD4 and inhibits the PI3K and Ras signaling pathways | Q39371861 | ||
| The iron chelators Dp44mT and DFO inhibit TGF-β-induced epithelial-mesenchymal transition via up-regulation of N-Myc downstream-regulated gene 1 (NDRG1). | Q39372971 | ||
| Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes. | Q39508023 | ||
| Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: a new strategy for the treatment of pancreatic cancer | Q39515084 | ||
| Overexpression of delta Np63 in a human nasopharyngeal carcinoma cell line downregulates CKIs and enhances cell proliferation | Q39904201 | ||
| Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents. | Q40113365 | ||
| Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion | Q40146601 | ||
| MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation | Q40323831 | ||
| Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation | Q40536203 | ||
| Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. | Q40550039 | ||
| Positive and negative regulation of ΔN-p63 promoter activity by p53 and ΔN-p63-α contributes to differential regulation of p53 target genes | Q40623341 | ||
| SUMO-1 modification of Mdm2 prevents its self-ubiquitination and increases Mdm2 ability to ubiquitinate p53. | Q40868752 | ||
| Overexpression of p21 protein in radiation-transformed mouse 10T(1/2) cell clones | Q40902305 | ||
| Agents that cause DNA double strand breaks lead to p16INK4a enrichment and the premature senescence of normal fibroblasts | Q41053539 | ||
| The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydra | Q41115819 | ||
| Iron deprivation inhibits cyclin-dependent kinase activity and decreases cyclin D/CDK4 protein levels in asynchronous MDA-MB-453 human breast cancer cells | Q41150221 | ||
| The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents | Q41268672 | ||
| The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell | Q41488824 | ||
| Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes | Q41532591 | ||
| Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. | Q42445479 | ||
| P433 | issue | 30 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 29694-29711 | |
| P577 | publication date | 2015-08-22 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Differential targeting of the cyclin-dependent kinase inhibitor, p21CIP1/WAF1, by chelators with anti-proliferative activity in a range of tumor cell-types | |
| P478 | volume | 6 |
| Q50944162 | Interplay of the iron-regulated metastasis suppressor NDRG1 with epidermal growth factor receptor (EGFR) and oncogenic signaling. | cites work | P2860 |
Search more.